Iterum Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $19.63 Mil.
During the past 12 months, Iterum Therapeutics's average Total Assets Growth Rate was -77.60% per year.
During the past 3 years, the average Total Assets Growth Rate was -47.30% per year.
During the past 5 years, the average Total Assets Growth Rate was -30.80% per year.
During the past 8 years, Iterum Therapeutics's highest 3-Year average Total Assets Growth Rate was 115.00%. The lowest was -47.30%. And the median was -8.70%.
The historical data trend for Iterum Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Iterum Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iterum Therapeutics (NAS:ITRM) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Iterum Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Iterum Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Iterum Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Iterum Therapeutics (Iterum Therapeutics) Business Description
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of innovative treatments for drug-resistant bacterial infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ITRM has been successfully added to your 